Rosa María Yáñez González

Dr. Rosa Mª Yáñez is a senior researcher specialist in immunology with more than 18 years’ experience in the field of mesenchymal stromal cells. Doctor of Medicine and Surgery from the Universidad Autónoma of Madrid (2003), she  started her professional training as a Resident Internal Biologist (BIR) in the Immunology Service in Puerta de Hierro hospital  (1997-2001), acquiring knowledge of the different areas of Clinical Immunology such as autoimmunity, immunodeficiencies, immunochemistry,  histocompatibility, transplants, flow cytometry and cell cultures. Within this period she also carried out the experimental work of her thesis entitled "Anti-idiotypic vaccination in patients with B lymphoma: immunological response and molecular remission", developed within a Clinical Protocol of Immunotherapy performed by the Hematology and Immunology Services of Puerta de Hierro hospital and defended in 2003. During this period of time, she participated in various immunotherapy protocols that were applied in two hematological diseases: low grade B lymphomas and multiple myelomas performed at Puerta de Hierro hospital in Madrid and at Clinica Universitaria of Navarra. 

In 2003 she joined the group of Hematopoietic Innovative Therapies of CIEMAT. During the period of 2003-2008 she collaborated in the development of a clinical protocol for gene therapy based on the generation of genetically modified T lymphocytes that expressed suicide genes for the treatment of graft versus host disease, carried out at CIEMAT. Since joining CIEMAT, she has developed a line of work investigating mesenchymal stromal cells (MSCs), of great interest both at the level of basic and translational research, studying their immunomodulatory properties and their application in different hematological pathologies such as graft versus host disease or hematopoietic graft failure in autologous transplant. Currently, she is working on the therapeutic improvement of MSCs by modifying them with messenger RNA and lentiviral vectors to increase their migration capacity and immunomodulatory properties. During this time, she has directed four theses, five master's degree projects and three final degree projects. She has 31 articles related to her professional career. Since 2013 she is the person in charge of Quality Control Department in the GMP facility Clinistem for the development of Medical Products in Advanced Therapy. And since 2017, she is also the head of this GMP facility.

Publications:

1.- Comparative proteomic analysis of nuclear and cytoplasmic compartments in human cardiac progenitor cells. Guillermo Albericio, Susana Aguilar, Jose Luis Torán,  Rosa Yañez, Juan Antonio López, Jesús Vázquez, Carmen Mora, Antonio Bernad. Sci Rep . 2022 Jan 7;12(1):146. doi: 10.1038/s41598-021-03956-8.

2.- Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10. Mª Rosario Hervás-Salcedo, María Fernández-García, Miriam Hernando-Rodriguez, Oscar Quintana-Bustamante, Jose-Carlos Segovia, Marcio Alvarez-Silva, Mariano García-Arranz, Pablo Minguez3, Victoria del Pozo, Marta Rodriguez de Alba, Damián García-Olmo, Carmen Ayuso, María Luisa Lamana, Juan A. Bueren and Rosa Yañez. Stem Cell Research and Therapy. 2021, 12:124 (doi.org/10.1186/s13287-021-02193-0) 

3.- The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve their Therapeutic Efficacy. David García-Bernal*, Mariano García-Arranz*, Rosa M. Yáñez*, Rosario Hervás-Salcedo, Alfonso Cortés, María Fernández-García, Miriam Hernando-Rodríguez, Óscar Quintana-Bustamante, Juan A. Bueren, Damián García-Olmo, Jose M. Moraleda, José C. Segovia, and Agustín G. Zapata.  Frontiers in Cell and Developmental Biology. 2021, vol 9 (doi: 10.3389/fcell.2021.650664)

4.- Involvement of Mesenchymal Stem Cells in Oral Mucosal Bacterial Immunotherapy. Alberto Vázquez, Lidia M. Fernández-Sevilla, Eva Jiménez, David Pérez-Cabrera1, Rosa Yáñez, Jose Luis Subiza, Alberto Varas, Jaris Valencia and Angeles Vicente. Frontiers in Immunology. Noviembre 2020, vol. 11, artículo 567391 (doi: 10.3389/fimmu.2020.567391)

5.- Natural estrogens enhance the engraftment of human hematopoietic stem and progenitor cells in immunodeficient mice. Sara Fañanas-Baquero, Israel Orman, Federico Becerra Aparicio, Silvia Bermudez de Miguel, Jordi Garcia Merino, Rosa Yañez, Yolanda, Fernandez Sainz, Rebeca Sánchez, Mercedes Dessy-Rodriguez, Omaira Alberquilla, David Alfaro, Agustin Zapata, Juan A Bueren, Jose Carlos Segovia and Oscar Quintana-Bustamante. Haematologica, 2020, 105 (doi:10.3324/haematol.2019.233924).

6.- Successful Engraftment of Gene Corrected Hematopoietic Stem Cells in Non-conditioned Fanconi Anemia Patients. Paula Rio, Susana Navarro, Wei Wang, Rebeca Sánchez-Domínguez, Roser M. Pujol, José C. Segovia, Massimo Bogliol, Eva Merino, Ning Wu, Rocío Salgado, María L. Lamana, Rosa M. Yañez, José A. Casado, Yari Giménez, Francisco J. Román-Rodríguez, Lara Álvarez, Omaira Alberquilla1, Anna Raimbault, Guillermo Guenechea, M. Luz Lozano, Laura Cerrato, Miriam Hernando, Eva Gálvez, Raquel Hladun, Irina Giralt, Jordi Barquinero, Anne Galy, Nagore García de Andoín, Ricardo López, Albert Catalá, Jonathan D. Schwartz, Jordi Surralles, Jean Soulier, Manfred Schmidt, Cristina Díaz de Heredia, Julián Sevilla, Juan A. Bueren. Nature Medine, 2019, vol 25, 1396-1401. (doi.org/10.1038/s41591-019-0550-z).

7.- A short and efficient transduction protocol of mouse hematopoietic stem cells with lentiviral vectors. María Fernández-García, Cristina Mesa, Elena Almarza, Juan Bueren and Rosa Yañez.  Hum Gene Ther Methods. 2017 Aug 17.  (doi: 10.1089/hgtb.2017.100).

8.- Mesenchymal stromal cells markedly improve the engraftment of gene-corrected hematopoietic stem cells in a mouse model of Fanconi Anemia. María Fernández-García, Maria Luisa Lamana, Miriam Hernando-Rodríguez, Rebeca Sánchez-Domínguez, Juan Bueren and Rosa Yañez. Human Gene Therapy. 2017 Aug 17. doi: 10.1089/hum.2017.076.

9.- Engraftment and in vivo proliferation advantage of gene corrected mobilized CD34+ cells from Fanconi anemia patients. Río P, Navarro S, Guenechea G, Sánchez-Domínguez R, Lamana ML, Yañez R, Casado JA, Mehta PA, Pujol MR, Surrallés J, Charrier S, Galy A, Segovia JC, Díaz de Heredia C, Sevilla J, Bueren J. Blood. 2017 Aug 11. pii: blood-2017-03-774174. doi: 10.1182/blood-2017-03-774174.

10.- Comparative analysis of the immunomodulatory capacities of human bone marrow– and adipose tissue–derived mesenchymal stromal cells from the same donor. Jaris Valencia, Belén Blanco, Rosa Yáñez, Miriam Vázquez, Carmen Herrero Sánchez, María Fernández-García, Concepción Rodríguez Serrano, David Pescador, Juan F. Blanco, Miriam Hernando-Rodríguez, Fermín Sánchez-Guijo, María Luisa Lamana, José Carlos Segovia, Ángeles Vicente, Consuelo Del Cañizo & Agustín G. Zapata. Cytotherapy, 2016; 18: 1297–1311.

11.- Mesenchymal stromal cells enhance the engraftment of hematopoietic stem cell in an autologous mouse transplantation model. María Fernandez-García, Rosa Mª Yáñez, Rebeca Sanchez-Dominguez, Miriam Hernando-Rodriguez, Miguel Peces-Barba, Guadalupe Herrera, Jose E. O’Connor, Jose Carlos Segovia, Juan A. Bueren, María L. Lamana. Stem Cell Research and Therapy (2015) 6:165 DOI 10.1186/s13287-015-0155-5

12.- Effect of mesenchymal stromal cells on the graft-vs-chronic myeloid leukemia effect in a mouse model of haploidentical bone marrow. Alberto Oviedo, Rosa Yáñez, Isabel Colmenero, Montserrat Aldea,  Antonio  Rubio,  Juan Bueren, Maria L. Lamana. Cell Transplantation (2013) 3109-3123.

13.- Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Rosa Yañez, Alberto Oviedo, Montserrat Aldea, Juan Bueren, Maria L. Lamana. Experimental Cell Research (2010) 3109-3123

14.- Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi Anemia patients. Jacome A., Navarro S., Río P., Yáñez R., González-Murillo A., Lozano ML., Lamana ML., Sevilla J., Olive T., Díaz-Heredia C., Badell I.  Estella J., Madero L., Guenechea G.,  Casado JA., Segovia JC. and Bueren JA. Molecular Therapy, vol 17, nº 6, 1083-1092, Junio 2009

15.- Adipose tissue-derived mesenchymal stem cells (AD-MSCs) have in vivo immunosuppressive properties applicable for the control of the graft versus-host disease (GVHD). Yáñez R., Lamana ML., García-Castro J., Colmenero I., Ramirez M., Bueren JA. Stem Cells 2006; 24:2582-2591